Evandro de Azambuja, MD, PhD
@E_de_Azambuja
Evandro de Azambuja, Breast cancer specialist @JulesBordet.
ESMO Director of Membership 2023-2024.
BSMO President 2023-2026.
ID:908351881008861184
http://www.bordet.be 14-09-2017 15:28:59
1,9K Tweets
3,8K Followers
933 Following
Follow People
Paolo Tarantino
MD, Research Fellow @DanaFarber | @harvardmed | @IEOufficiale | @LaStatale. Interested in breast oncology, HER2, ADCs & good music. Coffee expert.
ESMO - Eur. Oncology
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology communityโs work.
Matteo Lambertini, MD PhD
Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Prior @myESMO fellow. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia.
FabriceAndre
Head of Research Division of @GustaveRoussy , EiC @Annals_Oncology , โค๏ธ @ogcnice
Hope Rugo
#ESMO24 : ๐ฃLast 24 hours to submit. Watch Andres Cervantes, Rebecca Dent, Karin Jordan, Chris Verslype, Ann Partridge MD, MPH and Petros Grivas give excellent reasons to share your research. Deadline: 7 May 2024.
esmo.org/meeting-calendโฆ
Great to see our super Ospedale San Martino Genova Universitร di Genova fellow Luca Arecco, MD (now research fellow at Institut Jules Bordet Instituut with Evandro de Azambuja, MD, PhD) in the listโฆreally grateful to Conquer Cancer, the ASCO Foundation ASCO for supporting and motivating many young oncologists!
So much looking forward to #ASCO24
OncoAlert
First ESMO - Eur. Oncology Virtual Journal Club on May 22 at 630pm (CEST) - pencil down your agendas! Important data to be discussed by experts George Pentheroudakis FabriceAndre Solange Peters Andres Cervantes
esmo.org/about-esmo-meeโฆ
Very interesting #ESMOYOC #YO4YO session later todayโฆlooking forward to seeing you online !!!
ESMO - Eur. Oncology OncoAlert Maria Kfoury Vรฉronique Debien Joseph Ciccolini Universitร di Genova Ospedale San Martino Genova francescalongo Evandro de Azambuja, MD, PhD Andres Cervantes
ESMO Adaptation of Lines of Systemic Therapy ( EnLiST): Evandro de Azambuja, MD, PhD Diogo Martins Branco ESMO - Eur. Oncology
Brainstorming on EnLiST, the ESMO - Eur. Oncology ESMO Adaptation of Lines of Systemic Therapy, with Chris Twelves, Kamal Saini, Miriam Koopman, Suzette Delaloze, the ESMO Real World Data Digital Working Group and individual experts from EMA FDA Industry EORTC CRO Patient Advocates
Meeting past fellows in Brussels in an ESMO - Eur. Oncology activity Franzoi Maria Alice Diogo Martins Branco KS Saini, MD Institut Jules Bordet Instituut ULB ComRecherche #fellowship
#ESMO24 : Just under 1 month left to share your research ๐ฃ Discuss your findings with international, like-minded professionals who are shaping the future of #CancerPatient care. โฒ๏ธ Submit your abstract by 7 May 2024. ow.ly/X51l50RcStY
Andres Cervantes Rebecca Dent
important survey on digital health technology ESMO - Eur. Oncology Matteo Lambertini, MD PhD #digitalhealth #Oncology
Opening ceremony of ESMO - Eur. Oncology Summit Latin America in collaboration with SBOC Andres Cervantes Anelisa Coutinho
Many pts w/ HER2+ BC have long-term response to trastuzumab-pertuzumab โก๏ธ >16% without progression at 8y in #CLEOPATRA
In this analysis led by Vรฉronique Debien we show that complete response at first imaging re-evaluation correlates with longer PFS & OS
OncoAlert #bcsm
๐ ๐ก๐ฒ๐ ๐๐ฝ๐ถ๐๐ผ๐ฑ๐ฒ ๐๐น๐ฒ๐ฟ๐: '๐ช๐ต๐ฎ๐โ๐ ๐ก๐ฒ๐ ๐๐ผ๐ฐ? ๐ถ๐ป ๐๐ฟ๐ฒ๐ฎ๐๐ ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ' ๐
๐๐๐ฆ๐ง๐๐ก๐ฌ-๐๐ฟ๐ฒ๐ฎ๐๐๐ฌ๐ฐ ๐ง๐ฟ๐ถ๐ฎ๐น: ๐ง-๐๐ซ๐ฑ ๐ฆ๐ต๐ผ๐๐ ๐ฃ๐ฟ๐ผ๐บ๐ถ๐๐ฒ ๐ถ๐ป ๐๐๐ฅ๐ฎ-๐๐ผ๐ ๐๐ฟ๐ฒ๐ฎ๐๐ ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ
The DESTINY-Breast04 trial brings exciting news forโฆ
Now out in #ClinicalBreastCancer our subanalysis of the #CLEOPATRA study led by Vรฉronique Debien showing that patients with radiological complete response at 1๏ธโฃst disease re-evaluation have significantly โฌ๏ธ survival
OncoAlert
authors.elsevier.com/c/1inrj5RAAopuโฆ
Our last meta-analysis led by Guilherme Nader Marta shows that ctDNA detection๐งฌ๐ฉธin early #breastcancer is associated with โฌ๏ธ risk of recurrence, with mean lead time of 11 months
ctDNA detection had very high specificity for anticipating relapse
OncoAlert
authors.elsevier.com/sd/article/S20โฆ
๐ ๐ก๐ฒ๐ ๐๐ฝ๐ถ๐๐ผ๐ฑ๐ฒ ๐๐น๐ฒ๐ฟ๐: '๐ช๐ต๐ฎ๐โ๐ ๐ก๐ฒ๐ ๐๐ผ๐ฐ? ๐ถ๐ป ๐๐ฟ๐ฒ๐ฎ๐๐ ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ' ๐
Prof Evandro de Azambuja, MD, PhD and Dr Kevin Punie Unveil Novel Findings on Olaparib Efficacy, Examining Gene
Expression Profiles in the Agnostic PRECISION-2 Trial.
#ESMO24 : A place to share your research, explore promising areas of development and engage with the international #oncology community. ๐ฃ Submit your abstract by โฒ๏ธ 7 May 2024.
ow.ly/NYB450QEXU1
Andres Cervantes Rebecca Dent
๐ ๐ก๐ฒ๐ ๐๐ฝ๐ถ๐๐ผ๐ฑ๐ฒ ๐๐น๐ฒ๐ฟ๐: '๐ช๐ต๐ฎ๐โ๐ ๐ก๐ฒ๐ ๐๐ผ๐ฐ? ๐ถ๐ป ๐๐ฟ๐ฒ๐ฎ๐๐ ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ' ๐
Prof Evandro de Azambuja, MD, PhD and Dr Kevin Punie Explore KATHERIN Trial, Revolutionizing HER2+ Breast Cancer SOC Treatment and Validating iDFS as OS Surrogate Marker.
#ESMOBreast24 : Have a look at what experts such as Suzette Delaloge, Evandro de Azambuja, MD, PhD, Carmen Criscitiello, FabriceAndre, Mafalda Oliveira and Erika Hamilton, MD have to say to entice you to attend this event.
โฒ๏ธ Early registration deadline: 6 March 2024 ๐ow.ly/FCZK50QEUsl
#BCSM